• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

FDA 483 Inspectional Observations, dated 10/10-15/2004

 Note: Although this FDA-483 is an accurate representation of the original FDA-483 issued to the firm, it is not an exact copy. Slight modifications to the original FDA-483 have been made to accommodate its conversion to the HTML format. A scanned copy of the original letter is available in PDF at the bottom of this page.
  page 1 of 10 go toNext
DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
DISTRICT OFFICE ADDRESS AND PHONE NUMBER
ORA/OE/DIVISION OF COMPLIANCE MANAGEMENT AND OPERATIONS
5600 FISHERS LANE, ROCKVILLE, MD 20857 USA
TEL: (301) 827-0391/FAX: (301) 827-0342
DATE(S) OF INSPECTION
10/10-15/2004
FEI NUMBER
 
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT IS ISSUED
TO: ANDY SNEDDON, VICE PRESIDENT OF MANUFACTURING, UK SITE DIRECTOR
FIRM NAME
EVANS VACCINES an affiliate of CHIRON CORPORATION
STREET ADDRESS
GASKILL ROAD
CITY, STATE AND ZIP CODE
LIVERPOOL L24 9GR, UK
TYPE OF ESTABLISHMENT INSPECTED
VACCINE MANUFACTURER
THIS DOCUMENT LISTS OBSERVATIONS MADE BY THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OF YOUR FACILITY. THEY ARE INSPECTIONAL OBSERVATIONS, AND DO NOT REPRESENT A FINAL AGENCY DETERMINATION REGARDING YOUR COMPLIANCE. IF YOU HAVE AN OBJECTION REGARDING AN OBSERVATION, OR HAVE IMPLEMENTED, OR PLAN TO IMPLEMENT, CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY DISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESENTATIVE(S) DURING THE INSPECTION OR SUBMIT THIS INFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT FDA AT THE PHONE NUMBER AND ADDRESS ABOVE.

DURING AN INSPECTION OF YOUR FIRM (WE) OBSERVED:
  1. Regarding Fluvirin Sterility Investigation #R/0198/10/04 dated October 9th 2004:
    1. The Fluvirin Sterility Failure Investigation Report states (in part) that [ Redacted ] fumigation took place on May 17, 2004 as a corrective action to increased levels of Gram negative organisms (including Serratia spp) during April and May. The area fumigated was the formulation suite. The firm deemed that the fumigation “was successful, as confirmed by ongoing environmental monitoring” and that “it should be noted that there are no confirmed isolates of Serratia spp. within the Grade [ Redacted ] LAF unit where aseptic connections are made.” The firm further deems this as “a key assessment criteria for further batch processing as part of the Quality Assurance Process”. This investigation conclusion is not supported and information reported is inaccurate, in that:
      1. the firm does not report that Gram negative rods, oxidase negative, were actually isolated in the formulation areas after the fumigation, further Gram negative rods identified as Serratia spp. were also isolated, and
      2. there is no evidence that the firm took further action to correct continued excursions of alert and action levels in formulation rooms [ Redacted ] and [ Redacted ] from May 2004 through September 2004. The firm continued to experience alert and action level excursions for Gram negative organisms, including but not limited to, Serratia spp.
    2. Regarding retest performed on the sterility test failures for four of nine final vial product lots, there is no investigation into the mixed pass and fail sterility test results for the original two lots and two “sister” lots associated with the failed monovalents.

      The original two failed lots [ Redacted ] were retested [ Redacted ] times the normal test sample size (normal test sample size is [ Redacted ] vials). The “sister” lots [ Redacted ] of the two original failed lots were also retested [ Redacted ] times the normal test sample size. Results are as follows:
Lot# Re-Test Date Results of each set of [ Redacted ] vials
[ Redacted ] 22 Jul 04 [ Redacted ] set of [ Redacted ] vials passed sterility test
[ Redacted ] sets of [ Redacted ] vials failed sterility test
[ Redacted ] 22 Jul 04 [ Redacted ] sets of [ Redacted ] vials failed sterility test
SEE
REVERSE
OF THIS
PAGE

EMPLOYEE(S) SIGNATURE

[Handwritten Signatures]
Omotunde O. Osunsanmi
Paula A. Trost
John D. Finkbohner
David S. Cho
Mark A. Elengold

EMPLOYEE(S) NAME AND TITLE (Print or Type)
Omotunde O. Osunsanmi, CSO
Paula A. Trost, CSO
John D. Finkbohner, Ph.D. Supv. Chemist
David S. Cho, Ph.D., Microbiologist
Mark A. Elengold,Deputy Director Oper., CBER
DATE ISSUED
15 October 2004

 

FORM FDA 483 (4/03)      PREVIOUS EDITION OBSOLETE ( PSC Media Arts (301) 443-1090 EF)              INSPECTIONAL OBSERVATIONS PAGE 1 of 10 PAGES

  Page 1 of 10 go toNext
 Reverse Text on Page:
The observations of objectional conditions and practices listed on the front of this form are reported:
  1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
  2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.
Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC374(b)) provides:
"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgement, indicate that any food, drug, device, cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."
 

Return to: Page Top | EFOI Reading Room Start